The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer (2021)
Journal Article
Masisi, B. K., El Ansari, R., Alfarsi, L., Craze, M. L., Jewa, N., Oldfield, A., …Green, A. R. (2021). The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer. Cancers, 13(16), Article 3963. https://doi.org/10.3390/cancers13163963

Glutamine metabolism has a key role in the regulation of uncontrolled tumour growth. This study aimed to evaluate the expression and prognostic significance of glutaminase in luminal breast cancer (BC). The glutaminase isoforms (GLS/GLS2) were assess... Read More about The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer.

CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy (2019)
Journal Article
Alfarsi, L., Ansari, R. E., Craze, M. L., Toss, M. S., Masisi, B., Ellis, I. O., …Green, A. R. (2019). CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy. Breast Cancer Research and Treatment, 178(3), 535-544. https://doi.org/10.1007/s10549-019-05420-8

Purpose
Endocrine therapy is the standard treatment for oestrogen receptor positive (ER+) breast cancer. Despite its efficacy, around half of patients will develop resistance to this treatment and eventually relapse. Identification of effective and... Read More about CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.

The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer (2019)
Journal Article
El-Ansari, R., El Ansari, R., Craze, M. L., Alfarsi, L., Soria, D., Diez-Rodriguez, M., …Green, A. R. (2019). The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer. Breast Cancer Research and Treatment, 175(1), 27-38. https://doi.org/10.1007/s10549-018-05111-w

Purpose: Breast cancer (BC) is a heterogeneous disease characterised by variant biology, metabolic activity, and patient outcome. Glutamine availability for growth and progression of BC is important in several BC sub... Read More about The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer.

Glutamate dehydrogenase (GLUD1) expression in breast cancer (2018)
Journal Article
Craze, M. L., El-Ansari, R., Aleskandarany, M. A., Cheng, K. W., Al-Farsi, L., Masisi, B., …Green, A. R. (2019). Glutamate dehydrogenase (GLUD1) expression in breast cancer. Breast Cancer Research and Treatment, 174(1), 79–91. https://doi.org/10.1007/s10549-018-5060-z

Dysregulated cellular metabolism is regarded as one of the hallmarks of cancer with some tumours utilising the glutamine metabolism pathway for their sustained proliferation and survival. Glutamate dehydrogenase (GLUD1) is a key enzyme in glutaminoly... Read More about Glutamate dehydrogenase (GLUD1) expression in breast cancer.